University of Texas MD Anderson: Combination Therapy Well-Tolerated and Highly Effective for Patients With IDH1-Mutated Acute Myeloid Leukemia
May 29, 2020
May 29, 2020
HOUSTON, Texas, May 29 -- The University of Texas's MD Anderson Cancer Center issued the following news release:
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by researchers at The University of Texas MD Anderson Cancer Center. The results of this trial may support a novel course of action for patients with AML ha . . .
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by researchers at The University of Texas MD Anderson Cancer Center. The results of this trial may support a novel course of action for patients with AML ha . . .